Research Published in Nature Medicine Demonstrates the Immunological Effects of Tomivosertib, Including Inhibiting Production of Checkpoint Protein PD-L1 and Increasing T Cell Infiltration into Tumors
January 14, 2019 11:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced...
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
December 11, 2018 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced...
Data Presented at AACR Special Conference on PI3K/mTOR Signaling Demonstrates Potential of eFFECTOR’s eIF4E Inhibitors in Cancer
December 03, 2018 08:10 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced...
eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination with Checkpoint Inhibitors to Treat Patients with Insufficient Response to Checkpoint Inhibitors Alone
July 27, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Dosing of eFT508 in Phase 2 Expansion of Clinical Trial in Aggressive Form of Non-Hodgkin’s Lymphoma
June 06, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Initiates Randomized Dosing in Phase 2 Checkpoint Combination Trial of eFT508 and Avelumab in Colorectal Cancer
May 11, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it...
eFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal Chemistry
April 26, 2018 07:30 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 26, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that...
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting
April 16, 2018 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a...
eFFECTOR Announces Appointment of John W. Smither to its Board of Directors
March 23, 2018 14:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...
Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
December 11, 2017 10:00 ET
|
eFFECTOR Therapeutics
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR...